Selective serotonin receptor inverse agonists as therapeutics for disease
First Claim
Patent Images
1. A pharmaceutical composition comprising:
- a first compound selected from the group consisting of an inverse agonist of a serotonin receptor, an antagonist of a serotonin receptor, and pharmaceutically acceptable salts thereof; and
a second compound selected from the group consisting of a SSRI, a SNRI, a MAO-I, a TCA, an antipsychotic agent, a norepinephrine reuptake inhibitor, a dopamine agonist, an anti-insomnia drug, an anti-manic drug, an anti-phobia drug, the compound of Formula (II)and pharmaceutically acceptable salts thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-psychotic agent. Disclosed herein are also methods of treating psychotic disorders using the disclosed pharmaceutical compositions.
53 Citations
46 Claims
-
1. A pharmaceutical composition comprising:
-
a first compound selected from the group consisting of an inverse agonist of a serotonin receptor, an antagonist of a serotonin receptor, and pharmaceutically acceptable salts thereof; and
a second compound selected from the group consisting of a SSRI, a SNRI, a MAO-I, a TCA, an antipsychotic agent, a norepinephrine reuptake inhibitor, a dopamine agonist, an anti-insomnia drug, an anti-manic drug, an anti-phobia drug, the compound of Formula (II) and pharmaceutically acceptable salts thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 31)
-
-
23. A method of treating a disorder in a patient, the disorder selected from the group consisting of depression, mania, social phobia, psychosis, and a neuropsychiatric disorder, the method comprising:
-
identifying a patient in need of said treatment, and administering to said patient a therapeutically effective amount of a combination of a first compound and a second compound, the first compound selected from the group consisting of an inverse agonist of a serotonin receptor, an antagonist of a serotonin receptor, and pharmaceutically acceptable salts thereof, the second compound selected from the group consisting of a SSRI, a SNRI, a MAO-I, a TCA, an antipsychotic agent, a norepinephrine reuptake inhibitor, a dopamine agonist, an anti-insomnia drug, an anti-manic drug, an anti-phobia drug, the compound of Formula (II) and pharmaceutically acceptable salts thereof. - View Dependent Claims (24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeAcadia Pharmaceuticals Inc.
-
Original AssigneeAcadia Pharmaceuticals Inc.
-
InventorsDavis, Robert E., Brann, Mark R., Weiner, David M.
-
Application NumberUS10/854,035Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current514/217CPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/138 Aryloxyalkylamines, e.g. pr...A61K 31/445 Non condensed piperidines, ...A61K 31/4468 having a nitrogen directly ...A61K 45/06 Mixtures of active ingredie...A61K 9/0019 Injectable compositions; In...A61P 25/00 Drugs for disorders of the ...A61P 25/14 for treating abnormal movem...A61P 25/18 Antipsychotics, i.e. neurol...A61P 25/20 Hypnotics; SedativesA61P 25/22 AnxiolyticsA61P 25/24 AntidepressantsA61P 25/36 Opioid-abuseA61P 43/00 Drugs for specific purposes...
